Involvement of methylation-associated silencing of formin 2 in colorectal carcinogenesis

Table 5 Relationship between formin 2 methylation levels and clinicopathological data

Factor	No.	FMN2		P value
		Low, n (%)	High, n (%)
Age (yr)
< 60	136	66 (45.83)	70 (28.69)	0.00061
≥ 60	252	78 (54.17)	174 (71.31)
Gender
Male	210	72 (50.00)	138 (56.56)	0.2105
Female	178	72 (50.00)	106 (43.44)
Height (cm)
< 170	138	52 (48.60)	86 (47.25)	0.8250
≥ 170	151	55 (51.40)	96 (52.75)
Weight (kg)
< 80	156	56 (49.12)	100 (51.55)	0.6812
≥ 80	152	58 (50.88)	94 (48.45)
T
T1	11	5 (3.47)	6 (2.47)	0.4830
T2	54	16 (11.11)	38 (15.71)
T3	270	106 (73.61)	164 (67.77)
T4	51	17 (11.81)	34 (14.05)
N
N0	212	69 (47.92)	143 (59.34)	0.02931
N1 + N2	173	75 (52.08)	98 (40.66)
M
M0	264	98 (80.33)	166 (85.13)	0.2651
M1	53	24 (19.67)	29 (14.87)
Stage
I + II	197	62 (45.26)	135 (58.19)	0.01611
III + IV	172	75 (54.74)	97 (41.81)
Lymphovascular invasion
Yes	231	77 (60.63)	154 (72.99)	0.01801
No	107	50 (39.37)	57 (27.01)
Vascular invasion
Yes	78	31 (24.80)	47 (22.71)	0.6627
No	254	94 (75.20)	160 (77.29)
Perineural invasion
Yes	59	20 (24.39)	39 (26.53)	0.7225
No	170	62 (75.61)	108 (73.47)
Tumor status
Tumor-free	246	86 (71.07)	160 (77.29)	0.2094
Tumor-present	82	35 (28.93)	47 (22.71)
KRAS mutation
Yes	28	8 (42.11)	20 (54.05)	0.3972
No	28	11 (57.89)	17 (45.95)

¹Indicates a statistically significant result. TNM stage was defined according to the AJCC Cancer Staging Manual. Tumor status: The state or condition of an individual's neoplasm at a particular point in time.